Press Releases

Press Releases

Date Title & Summary Additional Formats
11/18/19
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year
Employee feedback places Cidara among top small companies in the area SAN DIEGO , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by
11/07/19
Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
SAN DIEGO , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2019 and provided an update on its corporate
11/05/19
Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs
SAN DIEGO , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14
10/03/19
Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences
SAN DIEGO , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases Society of America (IDSA) IDWeek 2019, which
09/16/19
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
SAN DIEGO , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Daruwala , chief operating officer, and James Levine , chief financial officer of Cidara are
09/03/19
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan , which will be
08/21/19
Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference
SAN DIEGO --(BUSINESS WIRE)--Aug. 21, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak ® antiviral program have
08/08/19
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
SAN DIEGO , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial results for the three months ended June 30, 2019 and provided an update on its corporate activities
08/07/19
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
SAN DIEGO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at the
07/29/19
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections Rezafungin met its objectives for efficacy, safety and tolerability Global Phase 3 ReSTORE trial